摘要目的:了解新型冠状病毒肺炎（COVID-19）住院患者合并肝损伤的临床特点、肝功能变化、影响因素及预后。方法:回顾性分析唐都医院隔离病房收治的40例COVID-19患者的一般情况、肝脏生物化学指标、凝血、血常规、UGT1A1*28基因多态性等资料，比较肝损伤组与肝功能正常组患者的肝损伤临床特点、影响因素以及预后。单因素分析中两样本均数比较采用 t检验，两个以上采用方差分析，计数资料采用χ 2检验，非正态分布计量资料以中位数描述，采用非参数检验。单因素分析中有统计学意义的影响因素作为自变量，采用多元logistic回归分析影响肝损伤的主要因素。 结果:40例患者中，男性25例（62.5%），女性15例（37.5%），年龄22～83（53.87±15.84）岁。疾病过程中出现肝功能损害的22例（55%）。患者丙氨酸转氨酶（ALT）和天冬氨酸转氨酶（AST）水平多在病程第2周开始升高，分别为正常值的4.4倍和3.5倍，伴同时段白蛋白下降，差异有统计学意义（ P < 0.001）。血总胆红素(TBil)异常者10例（43.5％），最高54.1 μmol/L，转氨酶的升高和血总胆红素的升高无相关关系( r = -0.006， P = 0.972）。3例患者凝血酶原活动度（PTA）低于50％，10例患者出现纤维蛋白降解产物（FDP）升高，13例出现D二聚体升高，均为重型或危重型患者。肝功能损害更易发生在使用药物种类多及使用激素量较大的患者中（ P = 0.002， P = 0.031），与UGT1A1*28基因位点TA6TA7突变无相关性。多元回归分析发现肝损伤发生仅与是否危重症相关。经常规保肝治疗，所有患者肝功能均在1周内恢复正常。 结论:COVID-19可能合并肝功能损害，以轻度转氨酶升高为主，多发生于病程第2周前后。重症患者发生肝损害比例更高，危重型是肝损伤发生的独立危险因素。

abstractsObjective:To understand the clinical characteristics, change of liver function, influencing factors and prognosis in hospitalized patients with coronavirus disease-19 (COVID-19) combined with liver injury.Methods:The general conditions, biochemical indicators of liver, blood clotting mechanism, routine blood test, UGT1A1 * 28 gene polymorphism and other data of 40 cases with COVID-19 admitted to the isolation ward of Tangdu Hospital were retrospectively analyzed. The clinical characteristics, influencing factors and prognosis of liver injury in patients with liver injury group and those with normal liver function group were compared. The mean of two samples in univariate analysis was compared by t-test and analysis of variance. The counting data was measured by χ 2 tests. The non-normal distribution measurement data were described by the median, and the non-parametric test was used. Statistically significant influencing factors were used as the independent variables in univariate analysis. Multiple logistic regression analysis was used to analyze the main influencing factors of liver injury. Results:Of the 40 cases, 25 were male (62.5%) and 15 were female (37.5%), aged 22 to 83 (53.87 ± 15.84) years. Liver injury was occurred in 22 cases (55%) during the course of the disease. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level was initially increased (4.4 to 3.5 times of the normal value) along with decrease of albumin in the second week, and the difference was statistically significant ( P < 0.001). Ten cases (43.5%) had highest abnormal total blood bilirubin (54.1 μmol/ L). There was no correlation between the increase in transaminase and the increase in total blood bilirubin ( R = -0.006, P = 0.972). Three cases had prothrombin activity (PTA) of ≤50%, 10 cases had elevated FDP, and 13 cases had elevated D-dimer, all of whom were severe or critically ill. Liver function injury was more likely to occur in patients who used many types of drugs and large amounts of hormones ( P = 0.002, P = 0.031), and there was no correlation with the TA6TA7 mutation in the UGT1A1 * 28 gene locus. Multiple regression analysis showed that the occurrence of liver injury was only related to critical illness. The liver function of all patients had recovered within one week after conventional liver protection treatment. Conclusion:COVID-19 combined with liver function injury may be due to the slight elevation of transaminase, mostly around the second week of the disease course. Severe patients have a higher proportion of liver injury, and critical type is an independent risk factor for liver injury.